Free Trial

Echelon Wealth Partners' Rating of Arbutus Biopharma on 10/4/2019

On October 4, 2019, Echelon Wealth Partners updated its outlook on Arbutus Biopharma (NASDAQ:ABUS) with the action "Downgrade", setting a "Sell" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.